NudC domain-containing protein 1 (NUDCD1)

NudC domain-containing protein 1 (NUDCD1), also known as CML66 or OVA66, is a member of the NudC family of co-chaperone/chaperone-like proteins that is characterized by the presence of a NudC domain[1][5]. NUDCD1 was initially identified as an overexpressed protein in chronic myelogenous leukemia and has since been recognized as highly immunogenic and upregulated in multiple tumor types, including colorectal, ovarian, cervical, lung, renal, and hepatocellular cancers[1][3][4]. NUDCD1 is a multifunctional protein involved in the regulation of diverse biological processes, notably cell proliferation, cell cycle progression, apoptosis, and epithelial-mesenchymal transition (EMT), frequently acting as an oncoprotein[3][4]. It has multiple isoforms due to alternative splicing[1]. Mechanistically, NUDCD1 promotes tumorigenesis by modulating cell proliferation, migration, invasion, and survival pathways such as the IGF1R-ERK1/2 and VEGF-VEGFR2 signaling axes[3][4]. In colorectal cancer, high NUDCD1 expression correlates with advanced tumor staging and poor prognosis, possibly through upregulation of spindle-assembly checkpoint genes (e.g., BUB1, BUBR1, MAD1, MPS1) and the LIS1/dynein pathway, and by shortening the S phase of the cell cycle[2]. NUDCD1 physically interacts with proteins involved in RNA splicing (such as DHX15) and possibly with coatomer and helicase complexes relevant to cellular trafficking and nucleic acid transactions[1][3]. In immunology, NUDCD1 is expressed in immune cells (notably CD8+ and CD4+ T cells) and certain gene variants in NUDCD1 (e.g., L252F) have been linked to severe infection outcomes, such as COVID-19, likely by affecting the NFκB signaling cascade and antiviral responses[6]. As a tumor antigen, NUDCD1 is also known as CML66, which has implications for immune recognition and possible autoimmune phenomena in the context of cancer or immunotherapy[4]. No specific small-molecule drugs or biologics are known to directly target NUDCD1 as of current literature. Its main relevance as a therapeutic target lies in cancer diagnosis (biomarker applications), potential vaccine/immunotherapy strategies, and prognosis[2][4]. Its diverse functions reflect its utility in both research and clinical pathology, particularly in oncology.

Other names

CML66OVA66FLJ14991Chronic myelogenous leukemia tumor antigen 66Tumor antigen CML66nudC domain-containing protein 1chronic myelogenous leukemia tumor antigen 66tumor antigen CML66